PMID- 12482123
OWN - NLM
STAT- MEDLINE
DCOM- 20030507
LR  - 20181113
IS  - 1357-0560 (Print)
IS  - 1357-0560 (Linking)
VI  - 19
IP  - 3
DP  - 2002
TI  - Correlation of sera TNF-alpha with percentage of bone marrow plasma cells, LDH, 
      beta2-microglobulin, and clinical stage in multiple myeloma.
PG  - 133-9
AB  - Tumor necrosis factor-alpha (TNF-alpha) is important for function, 
      differentiation, and transformation of B-lymphocytes in multiple myeloma (MM) but 
      can also induce apoptosis of myeloma cells. Based on this opposite effect, it is 
      very crucial to analyze the correlation of the serum level of TNF-alpha with 
      clinical parameters of the patients. In this article, we analyzed 18 MM patients, 
      48% male and 52% female, with a mean age of 52 yr (range: 35-81 yr), clinical 
      stage I in 21.4%, stage II in 26.4%, and stage III in 52.2% of patients. Patients 
      with advanced clinical stage, presence of osteolysis, and elevated lactate 
      dehydrogenase (LDH) had a significant difference (Mann-Whitney U-test, p < 0.05) 
      in the serum level of TNF-alpha in comparison with those in the early stage, 
      without osteolysis, and normal LDH. The correlation of individual values of 
      TNF-alpha with the percentage of plasma cells in the bone marrow, LDH, 
      beta2-microglobulin, fibrinogen, and sedimentation rate was significant (p < 
      0.05). However, we have not found a significant correlation between TNF-alpha and 
      concentration of hemoglobin, the number of white blood cells or platelets (p > 
      0.05). We concluded that our data indicate determination of TNF-alpha as a good 
      parameter for estimation of tumor mass presence, among individual patients with 
      MM, and may by used for monitoring during application of different therapy 
      protocols.
FAU - Jurisic, Vladimir
AU  - Jurisic V
AD  - Pathophysiology Departmnet, School of Medicine, University of Kragujevac, Serbia. 
      vdvd@mailcity.com
FAU - Colovic, Milica
AU  - Colovic M
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Med Oncol
JT  - Medical oncology (Northwood, London, England)
JID - 9435512
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 0 (beta 2-Microglobulin)
RN  - 9001-32-5 (Fibrinogen)
RN  - EC 1.1.1.27 (L-Lactate Dehydrogenase)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - *Biomarkers, Tumor
MH  - Blood Sedimentation
MH  - Bone Marrow Cells/pathology
MH  - Female
MH  - Fibrinogen/metabolism
MH  - Humans
MH  - L-Lactate Dehydrogenase/blood
MH  - Male
MH  - Middle Aged
MH  - Multiple Myeloma/blood/*physiopathology
MH  - Neoplasm Staging
MH  - Osteolysis/pathology
MH  - Plasma Cells/pathology
MH  - Tumor Necrosis Factor-alpha/*metabolism
MH  - beta 2-Microglobulin/metabolism
EDAT- 2002/12/17 04:00
MHDA- 2003/05/08 05:00
CRDT- 2002/12/17 04:00
PHST- 2002/12/17 04:00 [pubmed]
PHST- 2003/05/08 05:00 [medline]
PHST- 2002/12/17 04:00 [entrez]
AID - MO:19:3:133 [pii]
AID - 10.1385/MO:19:3:133 [doi]
PST - ppublish
SO  - Med Oncol. 2002;19(3):133-9. doi: 10.1385/MO:19:3:133.